311~314.胃癌患者外周血和肿瘤组织中高表达CD14 + DR low/- 髓源抑制性细胞[J].戴夫,李海文,彭琼,林沪,李元元.中国肿瘤生物治疗杂志,2011,18(3)

# 胃癌患者外周血和肿瘤组织中高表达CD14 + DR low/- 髓源抑制性细胞 点此下载全文

戴夫 李海文 彭琼 林沪 李元元

安徽医科大学 第三附属医院 消化内科，安徽 合肥 230061;安徽医科大学 第三附属医院 消化内科，安徽 合肥 230061;安徽医科大学 第三附属医院 消化内科，安徽 合肥 230061;解放军第302医院 生物治疗中心，北京 100039;解放军第302医院 生物治疗中心，北京 100039

**基金项目：**国家“十一五”科技重大专项（No. 2009ZX10004-309）

DOI：

**摘要：**

目的：探讨胃癌患者外周血和肿瘤组织中CD14 +DR low/- 髓源抑制性细胞（myeloid-derived suppressor cells，MDSCs）的表达及其与肿瘤病理特征的关系。方法：选取2009年3月至2010年10月安徽医科大学第三附属医院胃癌患者43例（Ⅰ期9例、Ⅱ期13例、Ⅲ期14例、Ⅳ期7例），另采集26例正常健康者作为对照组。流式细胞术检测外周血、瘤组织中CD14 + DR low/- MDSCs的表达水平，分析MDSCs表达水平与肿瘤病理特征的相关性。结果：胃癌患者肿瘤组织中CD14 + DR low/- MDSCs的表达显著高于自身外周和健康对照者外周血的表达水平\[2.87±1.93)% vs (2.37±1.7)%, (0.89±0.47)%, P <0 05和 P <0.01\]，后两者间差异也有统计学意义( P <0.01)。CD14 +DR low/- MDSCs的表达与胃癌的恶性程度呈正相关，晚期胃癌组织内CD14 + DR low/- MDSCs表达明显增加（Ⅰ：Ⅱ：Ⅲ：Ⅳ=(1.15±0.78)%：(1.71±0.92)%：(2.25±1.24)%：( 4.85± 2.37)%， P ＜0.05）。同时，肿瘤浸润组织与非浸润组织的CD14 + DR low/- MDSCs表达也有明显差异\[3.90±1.67)% vs (2 62±1.53)%， P <0.05\]。结论：CD14 + DR low/- MDSCs在胃癌患者外周血和肿瘤组织中均高表达，与胃癌的发生、发展密切相关。

**关键词：**胃癌 髓源的抑制性细胞 免疫逃逸 免疫监视

Myeloid-derived suppressor cells highly expressing CD14 +DR low/- in peripheral blood and tumor tissues of stomach carcinoma Download Fulltext

DAI Fu LI Hai-wen PENG Qiong LIN Hu LI Yuan-yuan

Department of Gastroenterology, Third Affiliated Hospital of Anhui Medical University, Hefei 230061, Anhui, China;Department of Gastroenterology, Third Affiliated Hospital of Anhui Medical University, Hefei 230061, Anhui, China;Department of Gastroenterology, Third Affiliated Hospital of Anhui Medical University, Hefei 230061, Anhui, China;Research Center for Biological Therapy, No. 302 Hospital of PLA, Beijing 100039, China;Research Center for Biological Therapy, No. 302 Hospital of PLA, Beijing 100039, China

Fund Project:Project supported by the National “the Eleventh Five-Year” Major Science and Technology Program of China (No. 2009ZX10004-309)

Abstract:

Objective:To investigate the expression of CD14 +DR low/- myeloid-derived suppressor cells (MDSCs) in peripheral blood and tumor tissues of gastric carcinoma (GC) patients and its relationship with clinicopathological of GC. Methods: Forty-three stomach carcinoma patients (9 stage Ⅰ, 13 stage Ⅱ, 14 stage Ⅲ, 7stage Ⅳ) were selected from Third Affiliated Hospital of Anhui Medical University (Mar. 2009 to Oct. 2010), and 26 healthy volunteers were used as control. CD14 +DR low/- MDSCs expression in peripheral blood and gastric carcinoma tissues was detected by flow cytometry, and its relationship with clinicopathological of GC was analyzed. Results: CD14 +DR low/- MDSCs expression in GC tissues was significantly higher than those in peripheral blood of GC patients and healthy controls (\[2.87±1.93\]% vs \[2 37±1.7\]%, \[0.89±0.47\]%, P <0.05 and P <0.01), and CD14 +DR low/- MDSCs expression in peripheral blood of GC patients was also higher than that in healthy controls ( P <0.01). CD14 +DR low/- MDSCs expression in GC tissues was positively correlated with their malignancy stage and significantly increased in advanced GC (stage Ⅰ：Ⅱ：Ⅲ：Ⅳ=( 1.15± 0.78)%：(1.71±0.92)%：(2.25±1.24)%：(4.85±2.37)%， P <0.05). Meanwhile, CD14 +DR low/- MDSCs expression in tumor infiltration tissues was significantly higher than that in tumor un-infiltration tissues (\[3.90±1 67)% vs \[2.62±1.53\]%, P <0.05). Conclusion: CD14 +DR low/- MDSCs are highly expressed in peripheral blood and GC tissues, and relates to the development and progression of GC.

Keywords:gastric carcinoma myeloid-derived suppressor cells immune escape immune surveillance

查看全文 查看/发表评论 下载PDF阅读器